Many of these models are established on the transgenic overexpression of human amyloid precursor protein (APP), combined with different familial AD-associated mutations in the APP gene, resulting in the production of different amyloid peptides that aggregate more easily [40,41,42]. This evidence concerns the gene APP and Alzheimer disease.